HEALTH INNOVATION. Health Innovation Innovation for health includes the development of new drugs,...
-
Upload
caitlin-lindsey -
Category
Documents
-
view
214 -
download
0
Transcript of HEALTH INNOVATION. Health Innovation Innovation for health includes the development of new drugs,...
HEALTH INNOVATION
Health Innovation
Innovation for health includes the
development of new drugs, vaccines,
diagnostics and medical devices, as
well as new techniques in process engineering and manufacturing, (and new approaches and policies in health systems and services, including a better understanding of human health behaviour)
2
DST’s role in health innovation guided by:
• The July 2011 National Health Research Summit;• The March 2006 Health Research Conference;• The National Research and Technology Foresight project of the Department of
Arts, Culture, Science and Technology (1998).• The White Paper on Science and Technology, 1996;• South Africa’s NRDS, 2002;• The National Health Act, Act 61 of 2004;• The National Nanotechnology Strategy, 2006;• The Medicine Control Amendment Bill, 2008;• The Ten Year Plan for Science and Technology, 2008;• The Technology Innovation Agency Act, Act 26 of 2008;• The Intellectual Property Rights Act, Act 51 of 2008;• The DST Corporate strategy 2014 – 2019;• The Bio-economy Strategy 2013;• The Industrial Policy Action Plan (IPAP2 2013-2016);• The National Development Plan (NDP 2030);• The Medium Term Strategic Framework (MTSF 2014-2019).
3
National Research and Development Strategy (2002)
Identified areas to form the core of the health research and innovation effort:
• Understanding the social impact of disease;
• Creating an environment and technologies to reduce the effect of poverty on the spread of disease;
• Developing care and support strategies;
• Understanding the challenges in providing access to prevention and care measures;
• Developing innovative preventative strategies;
• Developing novel therapeutic regimes, including the utilisation of indigenous knowledge;
• Developing preventive and therapeutic HIV/AIDS vaccines;
• Creating a viable vaccine manufacturing industry;
• Using appropriate forms of telemedicine to assist in transforming rural health care provision.
4
National Health Research Summit: July 2011
• Increased funding for health research by the DoH to achieve the 2% target of the national health budget;
• Training a new generation of health researchers, especially black people and women (through a proposed National Health Scholars Programme);
• Developing health research infrastructure in the Academic Health Complexes to facilitate research-based re-engineering of PHC (through funding of Clinical Research Centres);
• Funding of priority research projects designed to increase the lifespan of citizens (through a National Priority Research Projects Fund);
• Improving the national regulatory framework for health research;
• Creating a national mechanism for the timeous translation of research findings into policy, programmes and practice;
• Developing a national system for evidence-based planning, monitoring and evaluation of the effectiveness and impact of the health research system on the burden of disease in South Africa.
5
Top 10 causes of death for SA, Top 10 causes of death for SA, 1997 and 20101997 and 2010
Rank Cause No. of deaths % deaths ASDRs Rank Cause No. of
deaths%
deaths ASDRs
%Δ in ASDR
Persons 1997 Persons 2010
1 HIV/AIDS 55048 13.2 130.2 1 HIV/AIDS 191613 32.3 403.5 210%
2 Cerebrovascular disease 31844 7.7 118.0 2 Cerebrovascular disease 40124 6.8 114.1 -3%
3 Interpersonal violence 30770 7.4 74.5 3 Lower respiratory infections 36258 6.1 84.6 17%
4 Tuberculosis 28772 6.9 88.2 4 Tuberculosis 31252 5.3 74.0 -16%
5 Ischaemic heart disease 24917 6.0 94.2 5 Ischaemic heart disease 29613 5.0 83.9 -11%
6 Lower respiratory infections 24585 5.9 72.5 6 Hypertensive heart
disease 23518 4.0 73.4 4%
7 Diarrhoeal diseases 18985 4.6 45.9 7 Diarrhoeal diseases 21080 3.5 42.9 -6%
8 Hypertensive heart disease 18297 4.4 70.3 8 Diabetes mellitus 19310 3.3 54.0 29%
9 Road injuries 15275 3.7 38.4 9 Interpersonal violence 18685 3.1 36.5 -51%
10 Diabetes mellitus 11715 2.8 41.7 10 Road injuries 18480 3.1 37.6 -2%
Top 10 causes 260209 63 Top 10 causes 429933 72
Total 416209 100 1251 Total 594071 100 1402 12%
6
Build the Health Innovation System
Translational Architecture(ICTs, Knowledge Management, Modelling, Advanced Statistical Analysis)
New or improved therapeutics & drug
delivery systems
New vaccines and other biologicals
New or improved diagnostics
Market access / Impact
monitoring
New medical devices
Discovery
Development
DisseminationProduct development cycle
Technology development
Capacities & capabilities
Decision support
Technology & knowledge
transfer
7
Health Innovation Implementation
• Building the Health Innovation System
• Develop and support the translational architecture
• Support strategic priorities
8
Build the health innovation system
• Quadruple Helix collaboration• Market access and impact monitoring
– Engage with govt department responsible for market access (e.g. DoH, dti)– Establish market monitoring systems– Foresight exercises
• Capacity and capabilities: Training priorities– Determine and stimulate high priority areas for capacity-building
• Pharmaceutical discovery and development, preclinical testing, formulation, clinical trials and manufacturing (drugs and biologics/vaccines)
• Ethics in health research and innovation (human, animal, environmental);
• Innovation, product development and IP;• Monitoring clinical trials (both for community protection and to prevent
community push back); • Process development and scale-up (including the “good practices” -
GMP, GLP, GCLP). – Collaborate with Africa and rest of world to build and share expertise
9
• Technology development through Technology Platforms– Conduct an audit of South Africa’s innovation infrastructure– Create mechanisms for making required technology available (e.g.
platforms)• Technology and knowledge transfer
– Mechanisms, and incentives for international companies, to encourage knowledge transfer
– Mechanism to monitor and learn from technology and knowledge transfer activities
– Mechanism to encourage collaboration between local companies (e.g. Cape Health Technology Park)
• Product development cycle– Promoting the Quadruple Helix approach; – Mechanisms to incentivise the private sector to engage in product
development – Stimulate the development of piloting capacity in the public and private
sectors• Decision support
– review and coordinate legislation and regulations, policies, strategies and guidelines with research community inputs
• Monitoring and evaluation
Build the health innovation system (2)
10
Translational architecture
• Translational research
– Clinical Research and Clinical Trial abilities
• Tools and data analysis
– Development of ICT-based tools and technologies for epidemiology and other evidence-based methodologies
– Data analysis on individual genomes, validated biomarkers, and treatment outcomes
– Use of simple statistical analysis methods
• Information exchange
– Encourage knowledge exchange by research organisations and researchers
– Develop a knowledge translation framework
• Bioinformatics
• Bio-Portal
11
Implementation PrioritiesImplementation Priorities
• New or improved drugs, therapeutics and drug delivery systems;
• New vaccines or other biologicals
• New or improved diagnostics
• New medical devices;
12
Implementation PrioritiesImplementation Priorities
New or improved drugs, therapeutics and drug delivery systems– For diseases that pose the greatest health challenges to South Africa (HIV,
TB, Diabetes, Cancer, neonate)
– Precision medicine, and development of targeted therapies utilising a pan-omics approach such as genomics, transcriptomics, and proteomics combined with systems biology
– Reverse pharmacology approach in natural product drug research, with close link to African Traditional Medicine;
– Genetic manipulation and replacement and stem cell based therapies ( to reverse damage)
– New and simplified dosing regimes
– Drug delivery systems suited for SA conditions and environment
– Reverse engineering of high priority drugs to stimulate local manufacturing of APIs.
13
DRUG DEVELOPMENT VALUE CHAIN
Limited ability
Some ability
Established ability
Urgent Need
SA Capabiliites
Biop
rosp
ectin
g - I
nput
s
IKS Knowledge database
Gene-bank
Extract library
Compound library
Essential enabling technologies
BioinformaticsGenomics Proteomics
Small scale manufacturing
Phase I
Phase II A
Phase III
Manufacturing & Post market activities
API Manufacturing
Drug manufacturing
GAP Farming
7 years 2 years
Pharmaco-economic data collection
15 - 17 years
Target Discovery
Target identification
Target Validation
Assay Development
Lead discovery
Assay development
High Throughput Screening
Biochemistry & Enzymology
Medicinal Chemistry
Library development
Structure-based Drug design
Medicinal Chemistry
Cellular & Molecular Pharmacology
In Vitro drug activity
Cellular Disease Models
Drug Mechanism of Action
Preclinical Development
GLP upscaling
GLP Toxicology
ADMETox
Formulability CMC
Extended Pharmacological
profiling
Discovery
5 years 2 years
Metabolomics
Development Commercialisation
Phase II B
Registration
MCC
Clinical Trials
14
DRUG DEVELOPMENT
WADDP
15
VACCINE AND BIOLOGICALS
• Support local vaccine and biomarker discovery and development activities;
• Strengthen local vaccine manufacturing;
• Strengthen local biologics manufacturing capabilities.
7 years 2 years
15 - 17 years
5 years 2 years
16
New or improved diagnostics
• Point of care diagnostics, which need to be:– Accurate (specific, sensitive, stable);– Easy to use, access and afford;– Patient friendly, particularly by being minimally invasive;– Able to provide multiplex diagnosis.
• Personalised diagnostics:– Genetic (pathogen, host, predisposition); – Taking the technology required for the identification and characterisation of
infectious diseases to individuals by designing smart swabs, or portable hand-held devices (e.g. that analyse fluids).
• Rapid response capabilities:– Early detection of emerging diseases;– Novel ICTs for the capture, analysis and modelling of data for the early
detection of infectious disease events. • Environmental diagnostics:
– Identifying and managing contamination of water, air and food
17
New Medical Devices
• Build on excellent history– CAT scan (computer tomography scanners)
– Lodox
• Develop networks comprising of industry and academia and the science councils to encourage medical device innovation
18
MRC
DSTDoH
NRF
Science Councils
PPPs eg Biovac
Small companies
Platforms & service providers
Private sector
Pharmaceutical companies
Private sector not-for-profit
Aeras MMV
EDCTP
IDC -VCs
Research Institutes
Universities
SHIP
DTI
Government Departments
Funding Bodies
R & D
Local & International Private sector funders & Collaborators
ICGEB
GATES FOUNDATION
TIA
Enable partnershipsEnable partnerships
19